Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
Resource
Ann. Oncol., 26, 129-129
Journal
Ann. Oncol.
Journal Issue
26
Pages
129-129
Date Issued
2015
Date
2015
Author(s)
Mok, T.
Saijo, N.
Thongprasert, S.
Yang, J. C. -H.
Wu, Y. -L.
Young, H.
Haddad, V.
Jiang, H.
Fukuoka, M.